Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Biliary Tract Diseases

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 311 articles:
HTML format



Single Articles


    September 2021
  1. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
    The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
    PubMed     Abstract available


  2. AN J, Kim D, Oh B, Oh YJ, et al
    Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
    PubMed     Abstract available


    August 2021
  3. VEDELD HM, Grimsrud MM, Andresen K, Pharo HD, et al
    Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
    Hepatology. 2021 Aug 26. doi: 10.1002/hep.32125.
    PubMed     Abstract available


  4. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    PubMed     Abstract available


  5. ARORA M, Bogenberger JM, Abdelrahman AM, Yonkus J, et al
    Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers.
    Hepatology. 2021 Aug 18. doi: 10.1002/hep.32102.
    PubMed     Abstract available


  6. AMARACHINTHA SP, Mourya R, Ayabe H, Yang L, et al
    Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32107.
    PubMed     Abstract available


  7. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
    Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
    PubMed     Abstract available


  8. LIN Y, Cai Q, Chen Y, Shi T, et al
    CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
    PubMed     Abstract available


  9. ZENG R, Sha W, Leung FW, Chen H, et al
    Letter to the Editor: Proton pump inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality?
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32090.
    PubMed     Abstract available


    July 2021
  10. PANT K, Peixoto E, Richard S, Biswas A, et al
    Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32080.
    PubMed     Abstract available


  11. CAI P, Mao X, Zhao J, Nie L, et al
    Farnesoid X Receptor is Required for the Redifferentiation of Bi-potential Progenitor Cells during Biliary-Mediated Zebrafish Liver Regeneration.
    Hepatology. 2021 Jul 28. doi: 10.1002/hep.32076.
    PubMed     Abstract available


  12. GHOSH S, Devereaux MW, Anderson AL, Gehrke S, et al
    NFkappaB regulation of LRH-1 and ABCG5/8 potentiates phytosterol role in the pathogenesis of parenteral nutrition associated cholestasis.
    Hepatology. 2021 Jul 26. doi: 10.1002/hep.32071.
    PubMed     Abstract available


  13. LOBE C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, et al
    ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling.
    Hepatology. 2021 Jul 23. doi: 10.1002/hep.32069.
    PubMed     Abstract available


  14. ZHANG JW, Yang X, Ding HR, Zhang L, et al
    Is aspirin a drug or just a marker for biliary cancer?
    Hepatology. 2021 Jul 9. doi: 10.1002/hep.32052.
    PubMed     Abstract available


  15. LEE MH, Huang YH, Koshiol J
    Response Letter Regarding Article, "Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort".
    Hepatology. 2021 Jul 8. doi: 10.1002/hep.32051.
    PubMed     Abstract available


  16. DE GOEIJ FHC, Schlegel A, Muiesan P, Guarrera JV, et al
    Hypothermic oxygenated machine perfusion protects from cholangiopathy in DCD liver transplantation.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32044.
    PubMed     Abstract available


    June 2021
  17. VARTAK N, Drasdo D, Geisler F, Itoh T, et al
    On the mechanisms of biliary flux.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32027.
    PubMed     Abstract available


  18. SHI S, Chen S, Verstegen MMA, Pan Q, et al
    Letter to the Editor: HMGB1 Release is a Newly Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32026.
    PubMed     Abstract available


  19. MEADOWS V, Kennedy L, Ekser B, Kyritsi K, et al
    Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis via Farnesoid X Receptor Signaling.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32028.
    PubMed     Abstract available


  20. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
    The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
    PubMed     Abstract available


  21. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    PubMed     Abstract available


    May 2021
  22. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    PubMed     Abstract available


  23. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available


  24. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available


  25. KAMAL H, Sadr-Azodi O, Engstrand L, Brusselaers N, et al
    Association between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: a Swedish Population-Based Cohort Study.
    Hepatology. 2021 May 21. doi: 10.1002/hep.31914.
    PubMed     Abstract available


  26. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
    Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
    PubMed     Abstract available


  27. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    PubMed     Abstract available


  28. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    PubMed     Abstract available


  29. GENTILINI A, Lori G, Caligiuri A, Raggi C, et al
    Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31888.
    PubMed     Abstract available


  30. LIAO SF, Koshiol J, Huang YH, Jackson SS, et al
    Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31879.
    PubMed     Abstract available


  31. VAN DER LAAN LJW, Roos FJM, Verstegen MMA
    Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31877.
    PubMed     Abstract available


    April 2021
  32. YOON JG, Kim MH, Jang M, Kim H, et al
    Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses.
    Hepatology. 2021 Apr 21. doi: 10.1002/hep.31862.
    PubMed     Abstract available


    March 2021
  33. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
    A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
    Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
    PubMed     Abstract available


  34. BOERNER T, Drill E, Pak LM, Nguyen B, et al
    Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
    PubMed     Abstract available


  35. LUO X, Campbell NA, He L, O'Brien DR, et al
    SULF2 monoclonal antibody 5D5 suppresses human cholangiocarcinoma xenograft growth via regulation of a SULF2-PDGFRbeta-YAP signaling axis.
    Hepatology. 2021 Mar 18. doi: 10.1002/hep.31817.
    PubMed     Abstract available


  36. WADA Y, Shimada M, Yamamura K, Toshima T, et al
    A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
    PubMed     Abstract available


  37. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
    Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
    PubMed     Abstract available


  38. KENDRE G, Marhenke S, Lorz G, Becker D, et al
    The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
    PubMed     Abstract available


  39. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
    PubMed     Abstract available


  40. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
    Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
    PubMed     Abstract available


    February 2021
  41. CHIU M, Garabon J, Chen L, Karp N, et al
    Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
    PubMed     Abstract available


  42. JOHNSON KM, Fischer RT, Holtmann GJ, Shah A, et al
    Letter to the editor: Oral vancomycin versus no therapy for pediatric primary sclerosing cholangitis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31764.
    PubMed     Abstract available


  43. SHIOTA J, Samuelson LC, Razumilava N
    Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
    PubMed     Abstract available


  44. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available


  45. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
    HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
    PubMed     Abstract available


  46. JAVITT NB
    Letter to the Editor: Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31746.
    PubMed     Abstract available


  47. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
    PubMed     Abstract available


  48. ZHANG XF, Lv Y, Pawlik TM
    Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
    Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
    PubMed     Abstract available


    January 2021
  49. ITOH A, Adams D, Huang W, Wu Y, et al
    Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
    Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
    PubMed     Abstract available


  50. LI J, Ye X, He S
    Letter to the Editor: Imaging monitoring of primary sclerosing cholangitis patients.
    Hepatology. 2021 Jan 11. doi: 10.1002/hep.31709.
    PubMed     Abstract available


  51. ASSIS DN, Levy C
    Oral Vancomycin or Ursodeoxycholic acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
    Hepatology. 2021 Jan 5. doi: 10.1002/hep.31702.
    PubMed     Abstract available


    December 2020
  52. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
    Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
    Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
    PubMed     Abstract available


    November 2020
  53. KNOOIHUIZEN SAI, Aday A, Lee WM
    Ketamine-Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID-19.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31650.
    PubMed     Abstract available


  54. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
    Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
    PubMed     Abstract available


  55. KUNST RF, Verkade HJ, Oude Elferink RPJ, van de Graaf SFJ, et al
    Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31651.
    PubMed     Abstract available


  56. SATO K, Zhang W, Safarikia S, Isidan A, et al
    Organoids and spheroids as novel models for studying cholestatic liver injury and cholangiocarcinoma.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31653.
    PubMed     Abstract available


  57. COLYN L, Barcena-Varela M, Alvarez-Sola G, Latasa MU, et al
    Dual targeting of G9a and DNMT1 for the treatment of experimental cholangiocarcinoma.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31642.
    PubMed     Abstract available


  58. MEADOWS V, Francis H
    DCLK1 in Cholangiocarcinoma: Is this the biomarker and target we've been looking for?
    Hepatology. 2020 Nov 11. doi: 10.1002/hep.31630.
    PubMed     Abstract available


  59. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
    Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
    PubMed     Abstract available


    October 2020
  60. XU Y, Zhu Y, Hu S, Xu Y, et al
    Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
    Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
    PubMed     Abstract available


  61. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
    Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
    PubMed     Abstract available


  62. BRAGELMANN J, Barahona Ponce C, Marcelain K, Roessler S, et al
    Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31585.
    PubMed     Abstract available


  63. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available


    September 2020
  64. NEVI L, Di Matteo S, Carpino G, Zizzari I, et al
    DCLK1, a putative novel stem cell marker in human cholangiocarcinoma.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31571.
    PubMed     Abstract available


  65. EATON JE, Welle CL, Bakhshi Z, Sheedy SP, et al
    Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31575.
    PubMed     Abstract available


  66. CHEN D, Wu H, Feng X, Chen Y, et al
    DNA Methylation of CNRIP1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent PKM2 Ubiquitination.
    Hepatology. 2020 Sep 21. doi: 10.1002/hep.31561.
    PubMed     Abstract available


  67. DENEAU MR
    Oral vancomycin, ursodeoxycholic acid or no therapy for pediatric primary sclerosing cholangitis: a matched analysis.
    Hepatology. 2020 Sep 18. doi: 10.1002/hep.31560.
    PubMed     Abstract available


  68. CHEN L, Zhou T, White T, O'Brien A, et al
    The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
    PubMed     Abstract available


  69. BARAHONA PONCE C, Scherer D, Brinster R, Boekstegers F, et al
    Gallstones, Body Mass Index, C-reactive Protein and Gallbladder Cancer - Mendelian Randomization Analysis of Chilean and European Genotype Data.
    Hepatology. 2020 Sep 6. doi: 10.1002/hep.31537.
    PubMed     Abstract available


    August 2020
  70. MERDRIGNAC A, Papoutsoglou P, Coulouarn C
    Long non-coding RNAs in cholangiocarcinoma.
    Hepatology. 2020 Aug 31. doi: 10.1002/hep.31534.
    PubMed     Abstract available


  71. LUO Y, Brigham D, Bednarek J, Torres R, et al
    Unique cholangiocyte-targeted IgM autoantibodies correlate with poor outcome in biliary atresia.
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31504.
    PubMed     Abstract available


  72. FRISSEN M, Liao L, Schneider KM, Djudjaj S, et al
    Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury.
    Hepatology. 2020 Aug 4. doi: 10.1002/hep.31494.
    PubMed     Abstract available


  73. GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
    A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
    PubMed     Abstract available


  74. BAI X, Zhang H, Zhou Y, Nagaoka K, et al
    TET1 promotes malignant progression of cholangiocarcinoma with IDH1 wild-type.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31486.
    PubMed     Abstract available


  75. WU N, Baiocchi L, Zhou T, Kennedy L, et al
    The Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31484.
    PubMed     Abstract available


    July 2020
  76. AMZAL R, Thebaut A, Lapalus M, Almes M, et al
    Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
    Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
    PubMed     Abstract available


  77. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
    Reply to letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31471.
    PubMed     Abstract available


  78. XIAO Y, Chen Q, Xu G, Mao Y, et al
    Letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
    Hepatology. 2020 Jul 20. doi: 10.1002/hep.31470.
    PubMed     Abstract available


  79. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    PubMed    


    June 2020
  80. VAN IJZENDOORN SCD, Li Q, Qiu YL, Wang JS, et al
    Unequal effects of MYO5B mutations in liver and intestine determine the clinical presentation of low-GGT cholestasis.
    Hepatology. 2020 Jun 24. doi: 10.1002/hep.31430.
    PubMed     Abstract available


  81. VARTAK N, Guenther G, Joly F, Damle-Vartak A, et al
    Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
    Hepatology. 2020 Jun 19. doi: 10.1002/hep.31422.
    PubMed     Abstract available


  82. ABUD A, Maddur H, Salem R
    Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
    PubMed     Abstract available


  83. FABRIS L, Sato K, Alpini G, Strazzabosco M, et al
    The Tumor Microenvironment in Cholangiocarcinoma Progression.
    Hepatology. 2020 Jun 4. doi: 10.1002/hep.31410.
    PubMed     Abstract available


    May 2020
  84. DENEAU MR, Mack C, Perito ER, Ricciuto A, et al
    The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) index: a prognostic tool for children.
    Hepatology. 2020 May 28. doi: 10.1002/hep.31393.
    PubMed     Abstract available


  85. YAN C, Koda S, Wu J, Zhang BB, et al
    Roles of trained immunity in the pathogenesis of cholangiopathies: a novel therapeutic target.
    Hepatology. 2020 May 28. doi: 10.1002/hep.31395.
    PubMed     Abstract available


  86. GUNASEKARAN G, Bekki Y, Lourdusamy V, Schwartz M, et al
    Surgical Treatments of Hepatobiliary Cancers.
    Hepatology. 2020 May 21. doi: 10.1002/hep.31325.
    PubMed     Abstract available


  87. DEAN G, Hanauer S, Levitsky J
    The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications.
    Hepatology. 2020 May 11. doi: 10.1002/hep.31311.
    PubMed     Abstract available


  88. ZHANG Y, Wang H, Chen T, Wang H, et al
    C24 -Ceramide Drives Gallbladder Cancer Progression through Directly Targeting PIP4K2C to Facilitate mTOR Signaling Activation.
    Hepatology. 2020 May 6. doi: 10.1002/hep.31304.
    PubMed     Abstract available


  89. JAVITT NB
    Blocking Sodum-Taurocholate Cotransporting Polypeptide Stimulates Biliary Cholesterol and Phospholipid Secretion in Mice.
    Hepatology. 2020 May 4. doi: 10.1002/hep.31292.
    PubMed     Abstract available


    April 2020
  90. CHEN J, Vitetta L
    Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31269.
    PubMed     Abstract available


  91. O'ROURKE CJ, Munoz-Garrido P, Andersen JB
    Molecular targets in cholangiocarcinoma.
    Hepatology. 2020 Apr 18. doi: 10.1002/hep.31278.
    PubMed     Abstract available


  92. TRAUNER M, Chung C, Myers RP, Kowdley KV, et al
    Reply to HEP-20-0140 Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
    Hepatology. 2020 Apr 12. doi: 10.1002/hep.31268.
    PubMed     Abstract available


  93. LARGHI A, Rimbas M, Ardito F, Rizzatti G, et al
    EUS-FNA for lymph nodes staging in cholangiocarcinoma: should it become standard of care?
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31266.
    PubMed     Abstract available


  94. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    PubMed     Abstract available


    March 2020
  95. RIMLAND CA, Tilson SG, Morell CM, Tomaz RA, et al
    Regional differences in human biliary tissues and corresponding in vitro derived organoids.
    Hepatology. 2020 Mar 29. doi: 10.1002/hep.31252.
    PubMed     Abstract available


  96. VATS R, Liu S, Zhu J, Mukhi D, et al
    Impaired bile secretion promotes hepatobiliary injury in Sickle Cell Disease.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31239.
    PubMed     Abstract available


  97. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
    Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
    Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
    PubMed     Abstract available


  98. AZAD AI, Krishnan A, Troop L, Li Y, et al
    Targeted Apoptosis Of Ductular Reactive Cells Reduces Hepatic Fibrosis In A Mouse Model of Cholestasis.
    Hepatology. 2020 Mar 3. doi: 10.1002/hep.31211.
    PubMed     Abstract available


  99. LAVU S, Therneau TM, Harmsen WS, Mara KC, et al
    Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma.
    Hepatology. 2020 Mar 2. doi: 10.1002/hep.31146.
    PubMed     Abstract available


  100. LU ZN, Luo Q, Zhao LN, Shi Y, et al
    The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
    Hepatology. 2020;71:929-942.
    PubMed     Abstract available


    February 2020
  101. WANG HH, de Bari O, Arnatt CK, Liu M, et al
    Activation of a novel estrogen receptor GPR30 enhances cholesterol cholelithogenesis in female mice.
    Hepatology. 2020 Feb 29. doi: 10.1002/hep.31212.
    PubMed     Abstract available


  102. ZHU Y, Kwong LN
    Insights into the origin of intrahepatic cholangiocarcinoma from mouse models.
    Hepatology. 2020 Feb 24. doi: 10.1002/hep.31200.
    PubMed     Abstract available


  103. CHATURANTABUT S, Shwartz A, Garnaas MK, LaBella K, et al
    Estrogen acts via estrogen receptor 2b to regulate hepatobiliary fate during vertebrate development.
    Hepatology. 2020 Feb 14. doi: 10.1002/hep.31184.
    PubMed     Abstract available


  104. NAULT JC, Villanueva A
    Biomarkers for hepatobiliary cancers.
    Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
    PubMed     Abstract available


    January 2020
  105. MA W, Han C, Zhang J, Song K, et al
    The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
    Hepatology. 2020 Jan 28. doi: 10.1002/hep.31141.
    PubMed     Abstract available


  106. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC).
    Hepatology. 2020 Jan 23. doi: 10.1002/hep.31140.
    PubMed     Abstract available


  107. GOEPPERT B, Folseraas T, Roessler S, Kloor M, et al
    Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities.
    Hepatology. 2020 Jan 10. doi: 10.1002/hep.31110.
    PubMed     Abstract available


  108. LIN A, Alpert L, Hart J, Chapman C, et al
    Lymphoepithelioma-like carcinomas - a rare variant of cholangiocarcinoma.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31102.
    PubMed     Abstract available


  109. GOODE EC, Hirschfield GM, Rushbrook SM
    Reply.
    Hepatology. 2020;71:399-400.
    PubMed    


  110. WANG J, Geskus RB, Leeflang MMG, Ponsioen CY, et al
    Letter to the Editor: Fair Comparisons in the Arena of Risk Scores.
    Hepatology. 2020;71:398-399.
    PubMed    


    December 2019
  111. CAROTENUTO P, Hedayat S, Fassan M, Cardinale V, et al
    Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells.
    Hepatology. 2019 Dec 26. doi: 10.1002/hep.31094.
    PubMed     Abstract available


  112. JOB S, Rapoud D, Dos Santos A, Gonzalez P, et al
    Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Dec 25. doi: 10.1002/hep.31092.
    PubMed     Abstract available


  113. STUART L, Lambourne B, Turner P, Jones DE, et al
    HEP-19-1549 Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma.
    Hepatology. 2019 Dec 23. doi: 10.1002/hep.31089.
    PubMed     Abstract available


  114. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available


  115. LOZANO E, Asensio M, Perez-Silva L, Banales JM, et al
    MRP3-mediated chemoresistance in cholangiocarcinoma: Target for chemosensitization through restoring SOX17 expression.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31088.
    PubMed     Abstract available


  116. MALIKOWSKI T, Levy MJ, Gleeson FC, Storm AC, et al
    EUS-FNA is effective for lymph node staging in patients with cholangiocarcinoma.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31077.
    PubMed     Abstract available


  117. SHUNG DL, Assis DN
    Machine Learning in a Complex Disease: PREsTo Improves The Prognostication of Primary Sclerosing Cholangitis.
    Hepatology. 2019 Dec 18. doi: 10.1002/hep.31069.
    PubMed     Abstract available


  118. GUICCIARDI ME, Trussoni CE, LaRusso NF, Gores GJ, et al
    The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis.
    Hepatology. 2019 Dec 13. doi: 10.1002/hep.31067.
    PubMed     Abstract available


    November 2019
  119. OVEREEM AW, Li Q, Qiu YL, Carton-Garcia F, et al
    A molecular mechanism underlying genotype-specific intrahepatic cholestasis resulting from MYO5B mutations.
    Hepatology. 2019 Nov 21. doi: 10.1002/hep.31002.
    PubMed     Abstract available


  120. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available


    October 2019
  121. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
    Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
    PubMed     Abstract available


    September 2019
  122. LIU Y, Chen K, Li F, Gu Z, et al
    Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.
    Hepatology. 2019 Sep 30. doi: 10.1002/hep.30975.
    PubMed     Abstract available


  123. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available


  124. WAN ZH, Jiang TY, Shi YY, Pan YF, et al
    RPB5-mediating protein promotes cholangiocarcinoma tumorigenesis and drug resistance by competing with NRF2 for KEAP1 binding.
    Hepatology. 2019 Sep 21. doi: 10.1002/hep.30962.
    PubMed     Abstract available


  125. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    PubMed     Abstract available


  126. KIM HB, Elisofon SA
    Hepatology Elsewhere.
    Hepatology. 2019 Sep 13. doi: 10.1002/hep.30935.
    PubMed     Abstract available


  127. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    PubMed     Abstract available


  128. PRADHAN-SUNDD T, Kosar K, Saggi H, Zhang R, et al
    Wnt/beta-Catenin signaling plays a protective role in the Mdr2 KO murine model of cholestatic liver disease.
    Hepatology. 2019 Sep 6. doi: 10.1002/hep.30927.
    PubMed     Abstract available


    August 2019
  129. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
    A Bile Duct-on-a-Chip with Organ-Level Functions.
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30918.
    PubMed     Abstract available


  130. DIAO M, Li L, Cheng W
    Timing of choledochal cyst perforation.
    Hepatology. 2019 Aug 28. doi: 10.1002/hep.30902.
    PubMed     Abstract available


  131. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    PubMed     Abstract available


  132. BEUERS U, Hohenester S
    Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30906.
    PubMed     Abstract available


    July 2019
  133. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    PubMed     Abstract available


  134. CARPINO G, Nevi L, Overi D, Cardinale V, et al
    Peribiliary gland niche participates in biliary tree regeneration in mouse and in human primary sclerosing cholangitis.
    Hepatology. 2019 Jul 22. doi: 10.1002/hep.30871.
    PubMed     Abstract available


  135. LEE MH, Gao YT, Huang YH, McGee EE, et al
    A Metallomic Approach to Assess Associations of Serum Metal Levels With Gallstones and Gallbladder Cancer.
    Hepatology. 2019 Jul 18. doi: 10.1002/hep.30861.
    PubMed     Abstract available


  136. JIA X, Lu S, Zeng Z, Liu Q, et al
    Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Jul 12. doi: 10.1002/hep.30852.
    PubMed     Abstract available


  137. WU SH, Hsu JS, Chen HL, Chien MM, et al
    Plectin Mutations in Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2019 Jul 3. doi: 10.1002/hep.30841.
    PubMed     Abstract available


    June 2019
  138. UEASILAMONGKOL P, Khamphaya T, Guerra MT, Rodrigues M, et al
    Type 3 inositol 1,4,5-trisphosphate receptor is increased and enhances malignant properties in cholangiocarcinoma.
    Hepatology. 2019 Jun 28. doi: 10.1002/hep.30839.
    PubMed     Abstract available


  139. O'ROURKE CJ, Matter MS, Nepal C, Caetano-Oliveira R, et al
    Identification of a pan-gamma-secretase inhibitor response signature for notch-driven cholangiocarcinoma.
    Hepatology. 2019 Jun 18. doi: 10.1002/hep.30816.
    PubMed     Abstract available


    May 2019
  140. HE J, Chen J, Wei X, Leng H, et al
    mTORC1 Signaling is Required for the Dedifferentiation from Biliary Cell to Bi-potential Progenitor Cell in Zebrafish Liver Regeneration.
    Hepatology. 2019 May 28. doi: 10.1002/hep.30790.
    PubMed     Abstract available


  141. ROSCAM ABBING RLP, Slijepcevic D, Donkers JM, Havinga R, et al
    Blocking sodium-taurocholate cotransporting polypeptide stimulates biliary cholesterol and phospholipid secretion.
    Hepatology. 2019 May 28. doi: 10.1002/hep.30792.
    PubMed     Abstract available


  142. TERZIROLI BERETTA-PICCOLI B, Thompson R, Foskett P, Cerny A, et al
    A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adulthood.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30783.
    PubMed     Abstract available


  143. HOOGERLAND JA, Lei Y, Wolters JC, de Boer JF, et al
    Glucose-6-phosphate regulates hepatic bile acid synthesis in mice.
    Hepatology. 2019 May 18. doi: 10.1002/hep.30778.
    PubMed     Abstract available


  144. SIEW SM, Cunningham SC, Zhu E, Tay SS, et al
    Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy.
    Hepatology. 2019 May 17. doi: 10.1002/hep.30773.
    PubMed     Abstract available


  145. SUTHERLAND N, Li Wai Suen CFD, Mills C, Lokan J, et al
    Fibrosing cholestatic hepatitis-like syndrome in an immunocompetent patient with an acute flare of chronic hepatitis B.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30763.
    PubMed     Abstract available


  146. SITTITHUMCHAREE G, Suppramote O, Vaeteewoottacharn K, Sirisuksakun C, et al
    Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30704.
    PubMed     Abstract available


  147. JALAN-SAKRIKAR N, M De Assuncao T, Shi G, Aseem S, et al
    Proteasomal Degradation of Enhancer of Zeste Homologue 2 in Cholangiocytes Promotes Biliary Fibrosis.
    Hepatology. 2019 May 9. doi: 10.1002/hep.30706.
    PubMed     Abstract available


  148. XIAO Y, Liu R, Li X, Gurley EC, et al
    Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30698.
    PubMed     Abstract available


    April 2019
  149. ALISON MR, Lin WR
    Periportal Sox9-positive hepatocytes: progenitors with a biliary leaning.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30687.
    PubMed     Abstract available


  150. XIE Y, Matsumoto H, Kennedy S, Newberry EP, et al
    Impaired chylomicron assembly modifies hepatic metabolism through bile acid dependent and transmissible microbial adaptations.
    Hepatology. 2019 Apr 20. doi: 10.1002/hep.30669.
    PubMed     Abstract available


  151. LIU R, Li X, Zhu W, Wang Y, et al
    Cholangiocyte-derived exosomal LncRNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis.
    Hepatology. 2019 Apr 15. doi: 10.1002/hep.30662.
    PubMed     Abstract available


  152. OVADIA C, Perdones-Montero A, Spagou K, Smith A, et al
    Enhanced microbial bile acid deconjugation and impaired ileal uptake in pregnancy repress intestinal regulation of bile acid synthesis.
    Hepatology. 2019 Apr 15. doi: 10.1002/hep.30661.
    PubMed     Abstract available


  153. LOZANO E, Macias RIR, Monte MJ, Asensio M, et al
    Causes of hOCT1-dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor-selective gene therapy.
    Hepatology. 2019 Apr 10. doi: 10.1002/hep.30656.
    PubMed     Abstract available


  154. KOELFAT KVK, Plummer MP, Schaap FG, Lenicek M, et al
    Gallbladder dyskinesia is associated with an impaired postprandial FGF19 response in critically ill patients.
    Hepatology. 2019 Apr 1. doi: 10.1002/hep.30629.
    PubMed     Abstract available


    March 2019
  155. RIZZOLO D, Buckley K, Kong B, Zhan L, et al
    Bile acid homeostasis in a Cyp7a1 & Cyp27a1 double knockout mouse model.
    Hepatology. 2019 Mar 12. doi: 10.1002/hep.30612.
    PubMed     Abstract available


  156. WANG C, Zheng X, Jiang P, Tang R, et al
    Genome Wide Association Studies of Specific Antinuclear Autoantibody Sub-phenotypes in Primary Biliary Cholangitis.
    Hepatology. 2019 Mar 10. doi: 10.1002/hep.30604.
    PubMed     Abstract available


    February 2019
  157. WEN W, Schwabe RF
    Soluble fibers improve metabolic syndrome but may cause liver disease and hepatocellular carcinoma.
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30565.
    PubMed     Abstract available


  158. HONDA A, Tanaka A, Kaneko T, Komori A, et al
    Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30552.
    PubMed     Abstract available


  159. ZAGORY JA, Fenlon M, Dietz W, Zhao M, et al
    PROMININ-1 promotes biliary fibrosis associated with biliary atresia.
    Hepatology. 2019 Feb 5. doi: 10.1002/hep.30550.
    PubMed     Abstract available


    January 2019
  160. PRATT DS
    Hepatology Elsewhere.
    Hepatology. 2019 Jan 23. doi: 10.1002/hep.30517.
    PubMed     Abstract available


  161. BERAUER JP, Mezina AI, Okou DT, Sabo A, et al
    Identification of PKD1L1 Gene Variants in Children with the Biliary Atresia Splenic Malformation Syndrome.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30515.
    PubMed     Abstract available


  162. TRAUNER M, Gulamhusein A, Hameed B, Caldwell S, et al
    The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.
    Hepatology. 2019 Jan 19. doi: 10.1002/hep.30509.
    PubMed     Abstract available


  163. GOEPPERT B, Toth R, Singer S, Albrecht T, et al
    Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30493.
    PubMed     Abstract available


  164. HEERKENS M, Dedden S, Scheepers H, Van Paassen P, et al
    Effect of plasmapheresis on cholestatic pruritus and autotaxin activity during pregnancy.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30496.
    PubMed     Abstract available


    December 2018
  165. XIE C, Duffy AG, Mabry-Hrones D, Wood B, et al
    Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer.
    Hepatology. 2018 Dec 22. doi: 10.1002/hep.30482.
    PubMed     Abstract available


  166. GOODE EC, Clark AB, Mells GM, Srivastava B, et al
    Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
    Hepatology. 2018 Dec 19. doi: 10.1002/hep.30479.
    PubMed     Abstract available


  167. SOROKA CJ, Assis DN, Alrabadi LS, Roberts S, et al
    Bile-derived organoids from patients with primary sclerosing cholangitis recapitulate their inflammatory immune profile.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30470.
    PubMed     Abstract available


  168. FUNKE K, Rockey DC
    Cholestatic drug induced liver injury caused by mifepristone.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30465.
    PubMed     Abstract available


  169. MARONI L, Pinto C, Giordano DM, Saccomanno S, et al
    Ageing-related expression of Twinfilin-1 regulates cholangiocyte biological response to injury.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30466.
    PubMed     Abstract available


  170. RAND EB
    Cirrhotic Cardiomyopathy in children with BA: A new objective parameter to predict morbidity and mortality on the waitlist - and beyond!
    Hepatology. 2018 Dec 12. doi: 10.1002/hep.30419.
    PubMed     Abstract available


  171. HUANG L, Cai J, Guo H, Gu J, et al
    ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30404.
    PubMed     Abstract available


  172. KHAMBU B, Li T, Yan S, Yu C, et al
    Hepatic Autophagy Deficiency Compromises FXR Functionality and Causes Cholestatic Injury.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30407.
    PubMed     Abstract available


  173. WANG F, Wang J, Li Y, Yuan J, et al
    Gallstone disease and type 2 diabetes risk: A Mendelian randomization study.
    Hepatology. 2018 Dec 4. doi: 10.1002/hep.30403.
    PubMed     Abstract available


  174. DE JONG IEM, Matton APM, van Praagh JB, van Haaften WT, et al
    Peribiliary glands are key in regeneration of the human biliary epithelium after severe bile duct injury.
    Hepatology. 2018 Dec 2. doi: 10.1002/hep.30365.
    PubMed     Abstract available


    November 2018
  175. SANTAMARIA E, Rodriguez-Ortigosa CM, Uriarte I, Latasa MU, et al
    The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis.
    Hepatology. 2018 Nov 8. doi: 10.1002/hep.30348.
    PubMed     Abstract available


  176. TIRNITZ-PARKER JEE, Forbes SJ, Olynyk JK, Ramm GA, et al
    Cellular plasticity in liver regeneration - spotlight on cholangiocytes.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30340.
    PubMed     Abstract available


    October 2018
  177. CASTRO NARRO GE, Gamboa Dominguez A, Consuelo Sanchez A, Salazar Martinez A, et al
    Combined Hepatocellular-Cholangiocarcinoma in a Patient with Cirrhosis due to Cholesteryl Ester Storage Disease.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30331.
    PubMed     Abstract available


  178. BANALES JM, Inarrairaegui M, Arbelaiz A, Milkiewicz P, et al
    Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30319.
    PubMed     Abstract available


  179. GELLERT-KRISTENSEN H, Dalila N, Nielsen SF, Nordestgaard BG, et al
    Identification and replication of six new loci associated with gallstone disease.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30313.
    PubMed     Abstract available


  180. ANEZ-BUSTILLOS L, Dao DT, Potemkin AK, Perez-Atayde AR, et al
    An Intravenous Fish Oil Based Lipid Emulsion successfully treats intractable pruritus and cholestasis in a patient with MVID.
    Hepatology. 2018 Oct 12. doi: 10.1002/hep.30311.
    PubMed     Abstract available


  181. MANSINI AP, Peixoto E, Jin S, Richard S, et al
    The chemosensory function of primary cilia regulates cholangiocyte migration, invasion and tumor growth.
    Hepatology. 2018 Oct 9. doi: 10.1002/hep.30308.
    PubMed     Abstract available


  182. PERUGORRIA MJ, Olaizola P, Banales JM
    Cholangiocyte-to-Hepatocyte Differentiation: a Context Dependent Process and an Opportunity for Regenerative Medicine.
    Hepatology. 2018 Oct 8. doi: 10.1002/hep.30305.
    PubMed     Abstract available


    September 2018
  183. SIRICA AE, Gores GJ, Groopman JD, Selaru FM, et al
    Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30289.
    PubMed     Abstract available


  184. CAI SY, Boyer JL
    Bile Infarcts - new insights into the pathogenesis of obstructive cholestasis.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30291.
    PubMed     Abstract available


  185. BLOKKER BA, Maijo M, Echeandia M, Galduroz M, et al
    Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease.
    Hepatology. 2018 Sep 19. doi: 10.1002/hep.30275.
    PubMed     Abstract available


  186. RUSSELL JO, Lu WY, Okabe H, Abrams M, et al
    Hepatocyte-specific beta-catenin deletion during severe liver injury provokes cholangiocytes to differentiate into hepatocytes.
    Hepatology. 2018 Sep 14. doi: 10.1002/hep.30270.
    PubMed     Abstract available


  187. KAMATH B, Mack CL
    From hepatocyte to cholangiocyte: the remarkable potential of transdifferentiation to treat cholestatic diseases.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30250.
    PubMed     Abstract available


    August 2018
  188. MUIR AJ, Levy C, Janssen HLA, Montano-Loza AJ, et al
    Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
    Hepatology. 2018 Aug 28. doi: 10.1002/hep.30237.
    PubMed     Abstract available


  189. YANG L, Zhou Y, Xu PP, Mourya R, et al
    Diagnostic Accuracy of Serum Matrix Metalloproteinase-7 for Biliary Atresia.
    Hepatology. 2018 Aug 28. doi: 10.1002/hep.30234.
    PubMed     Abstract available


  190. FRANCA A, Filho ACML, Guerra MT, Weerachayaphorn J, et al
    Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30228.
    PubMed     Abstract available


  191. CARPINO G, Cardinale V, Folseraas T, Overi D, et al
    Neoplastic transformation of peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30210.
    PubMed     Abstract available


  192. GHALLAB A, Hofmann U, Sezgin S, Vartak N, et al
    Bile micro-infarcts in cholestasis are initiated by rupture of the apical hepatocyte membrane and cause shunting of bile to sinusoidal blood.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30213.
    PubMed     Abstract available


  193. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    PubMed     Abstract available


  194. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    PubMed     Abstract available


  195. LAMBERTI D, Cristinziano G, Porru M, Leonetti C, et al
    HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma.
    Hepatology. 2018 Aug 1. doi: 10.1002/hep.30127.
    PubMed     Abstract available


    July 2018
  196. LOOMES KM, Spino C, Goodrich NP, Hangartner TN, et al
    Bone Density in Children with Chronic Liver Disease Correlates with Growth and Cholestasis.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30196.
    PubMed     Abstract available


  197. OGAWA K, Kamimura K, Terai S
    Anti-Programmed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.
    Hepatology. 2018 Jul 23. doi: 10.1002/hep.30189.
    PubMed     Abstract available


  198. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    PubMed     Abstract available


    May 2018
  199. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    PubMed     Abstract available


  200. LIAN M, Wang Q, Jiang X, Zhang J, et al
    The Immunobiology of RANKL and Myeloid Derived Suppressor Cell Activation in IgG4-related Sclerosing Cholangitis.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30095.
    PubMed     Abstract available


  201. EATON JE, Vesterhus M, McCauley BM, Atkinson EJ, et al
    Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes in PSC: A Derivation & Validation Study Using Machine Learning.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30085.
    PubMed     Abstract available


  202. TAYLOR SA, Green RM
    Bile acids, microbiota and metabolism.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30078.
    PubMed    


    April 2018
  203. RIZVI S, Gores GJ
    Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking through a Door Half-opened.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.30069.
    PubMed    


  204. TAYLOR AE, Carey AN, Kudira R, Lages CS, et al
    Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30061.
    PubMed     Abstract available


  205. BEDNAREK J, Traxinger B, Brigham D, Roach J, et al
    Cytokine-producing B cells promote immune-mediated bile duct injury in murine biliary atresia.
    Hepatology. 2018 Apr 20. doi: 10.1002/hep.30051.
    PubMed     Abstract available


  206. KONG B, Sun R, Huang M, Chow MD, et al
    A Novel Fibroblast Growth Factor 15 Dependent- and Bile Acid Independent-Promotion of Liver Regeneration in Mice.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30041.
    PubMed     Abstract available


    March 2018
  207. BEZERRA JA, Wells RG, Mack CL, Karpen SJ, et al
    BILIARY ATRESIA: Clinical and Research Challenges for the 21(st) Century.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29905.
    PubMed     Abstract available


  208. HOFMANN AF, Marschall HU
    Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29909.
    PubMed    


  209. SOUFI N, Kohli R
    What's cold got to do with it? Cold induced thermogenesis and microbiome modification maybe regulated by bile acid physiology.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29899.
    PubMed    


  210. KENNEDY L, Hargrove L, Demieville J, Karstens A, et al
    Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2(-/-) mice and human cholangiocarcinoma tumorigenesis.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29898.
    PubMed     Abstract available


  211. PONSIOEN CY, Lindor KD, Mehta R, Dimick-Santos L, et al
    Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis.
    Hepatology. 2018 Mar 25. doi: 10.1002/hep.29882.
    PubMed     Abstract available


  212. SLIJEPCEVIC D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, et al
    NTCP inhibition has hepatoprotective effects in cholestasis in mice.
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29888.
    PubMed     Abstract available


    February 2018
  213. PATHAK P, Cen X, Nichols RG, Ferrell JM, et al
    Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29857.
    PubMed     Abstract available


  214. WU JF, Lee CS, Lin WH, Jeng YM, et al
    Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29856.
    PubMed     Abstract available


  215. LI X, Liu R, Huang Z, Gurley EC, et al
    Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and human.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29838.
    PubMed     Abstract available


  216. MANSINI AP, Lorenzo Pisarello MJ, Thelen KM, Cruz-Reyes M, et al
    MiR-433 and miR-22 dysregulations induce HDAC6 overexpression and ciliary loss in cholangiocarcinoma.
    Hepatology. 2018 Feb 6. doi: 10.1002/hep.29832.
    PubMed     Abstract available


  217. OLAIZOLA P, Perugorria MJ, Banales JM
    Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients.
    Hepatology. 2018 Feb 2. doi: 10.1002/hep.29830.
    PubMed    


    January 2018
  218. LI Q, Dutta A, Kresge C, Bugde A, et al
    Bile acids stimulate cholangiocyte fluid secretion by activation of membraneTMEM16A Cl(-) channels.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29804.
    PubMed     Abstract available


  219. BRUNT E, Aishima S, Clavien PA, Fowler K, et al
    cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29789.
    PubMed     Abstract available


  220. GULAMHUSEIN AF, Lazaridis KN
    Primary Biliary Cholangitis, DNA and Beyond: The Relative Contribution of Genes.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29783.
    PubMed    


  221. ARNDTZ K, Hirschfield GM
    Quality of life and primary sclerosing cholangitis: the business of defining what counts.
    Hepatology. 2018 Jan 9. doi: 10.1002/hep.29775.
    PubMed    


    December 2017
  222. NEPAL C, O'Rourke CJ, Oliveira DV, Taranta A, et al
    Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2017 Dec 26. doi: 10.1002/hep.29764.
    PubMed     Abstract available


  223. BAJAJ JS, Hylemon PB
    Gut-Liver Axis Alterations in Alcoholic Liver Disease: Are Bile Acids the Answer?
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29760.
    PubMed    


  224. SO J, Khaliq M, Evason K, Ninov N, et al
    Wnt/beta-catenin signaling controls intrahepatic biliary network formation in zebrafish by regulating Notch activity.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29752.
    PubMed     Abstract available


  225. ALI AH, Tabibian JH, Naser-Ghodsi N, Lennon RJ, et al
    Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis.
    Hepatology. 2017 Dec 15. doi: 10.1002/hep.29730.
    PubMed     Abstract available


  226. LEVY C
    Evolving role of Obeticholic acid in primary biliary cholangitis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29726.
    PubMed    


  227. MURILLO PEREZ F, Goet JC, Lammers WJ, Gulamhusein A, et al
    Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29717.
    PubMed     Abstract available


  228. LEVY D
    The role of mEH, NTCP and OATP in hepatic sodium-dependent bile acid transport.
    Hepatology. 2017 Dec 6. doi: 10.1002/hep.29712.
    PubMed    


  229. BOWLUS CL
    Scratching the surface of cholestatic itch treatments.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29698.
    PubMed    


    November 2017
  230. ONO SK, Bassit L, Van Vaisberg V, Avancini Ferreira Alves V, et al
    Acute acalculous cholecystitis during Zika virus infection in an immunocompromised patient.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29682.
    PubMed    


  231. ORNOLFSSON KT, Olafsson S, Bergmann OM, Gershwin ME, et al
    Using the Icelandic Genealogical Database to define the familial risk of primary biliary cholangitis.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29675.
    PubMed     Abstract available


  232. HARTMANN P, Hochrath K, Horvath A, Chen P, et al
    Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29676.
    PubMed     Abstract available


  233. YOUNOSSI ZM, Afendy A, Stepanova M, Racila A, et al
    Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29664.
    PubMed     Abstract available


  234. SHARMA A, Gandhi CR
    "CHOP"ing intestinal stem cells on way to cholestatic liver injury.
    Hepatology. 2017 Nov 16. doi: 10.1002/hep.29656.
    PubMed    


  235. AFONSO MB, Rodrigues CMP
    microRevolution in understanding primary biliary cholangitis pathophysiology.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29653.
    PubMed    


  236. SCHRAMM C, Eaton J, Ringe KI, Venkatesh S, et al
    Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group.
    Hepatology. 2017;66:1675-1688.
    PubMed     Abstract available


  237. ELLIS JL, Bove KE, Schuetz EG, Leino D, et al
    Zebrafish abcb11b mutant reveals novel strategies to restore bile excretion impaired by bile salt export pump deficiency.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29632.
    PubMed     Abstract available


  238. CARBONE M, Bonato G, Invernizzi P
    Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29625.
    PubMed    


    October 2017
  239. JANSEN PLM
    Hydrodynamics of bile flow Lessons from computational modelling.
    Hepatology. 2017 Oct 27. doi: 10.1002/hep.29618.
    PubMed    


  240. LIASKOU E, Hirschfield GM
    Genetic association studies and the risk factors for developing the 'immuno-bile-logic' disease PBC.
    Hepatology. 2017 Oct 24. doi: 10.1002/hep.29603.
    PubMed    


  241. JALAN-SAKRIKAR N, Huebert RC
    Ducts in a Dish: Bioengineered Biliary Scaffolds for Regenerative Medicine.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29614.
    PubMed    


  242. EHRLICH L, Glaser SS
    Novel beta-catenin/FXR Interaction Regulates Hepatic Bile Acid Metabolism During Cholestasis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29584.
    PubMed    


  243. KOWDLEY KV, Luketic V, Chapman R, Hirschfield GM, et al
    A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29569.
    PubMed     Abstract available


  244. FERANCHAK AP
    CFTR: Actin(g) as a master regulator of cholangiocyte function.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29583.
    PubMed    


  245. MASYUK AI, Masyuk TV, Lorenzo Pisarello MJ, Ding JF, et al
    Cholangiocyte Autophagy Contributes to Hepatic Cystogenesis in Polycystic Liver Disease and Represents a Potential Therapeutic Target.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29577.
    PubMed     Abstract available


  246. PRADHAN-SUNDD T, Zhou L, Vats R, Jiang A, et al
    Dual catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic cholestasis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29585.
    PubMed     Abstract available


    September 2017
  247. LIU R, Li X, Huang Z, Zhao D, et al
    CHOP-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29540.
    PubMed     Abstract available


  248. JAHN D, Geier A
    Bile acids in NASH: pathophysiological driving force or innocent bystanders?
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29543.
    PubMed    


  249. ERICE O, Munoz-Garrido P, Vaquero J, Perugorria MJ, et al
    MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
    Hepatology. 2017 Sep 18. doi: 10.1002/hep.29533.
    PubMed     Abstract available


  250. BAE HR, Hodge DL, Yang GX, Leung PSC, et al
    The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29524.
    PubMed     Abstract available


  251. SULTAN M, Rao A, Elpeleg O, Vaz FM, et al
    Organic Solute Transporter-beta (SLC51B) Deficiency in Two Brothers with Congenital Diarrhea and Features of Cholestasis.
    Hepatology. 2017 Sep 12. doi: 10.1002/hep.29516.
    PubMed     Abstract available


  252. LUO Z, Jegga AG, Bezerra JA
    Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.
    Hepatology. 2017 Sep 2. doi: 10.1002/hep.29504.
    PubMed     Abstract available


  253. DELLAVANCE A, Ferraz MLG, Cancado ELR, Andrade LEC, et al
    Expansion and intensification of humoral autoimmune response in the transition from preclinical to full-blown primary biliary cholangitis.
    Hepatology. 2017;66:997.
    PubMed    


    August 2017
  254. VYAS D, Baptista PM, Brovold M, Moran E, et al
    Self-assembled liver organoids recapitulate hepato-biliary organogenesis in vitro.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29483.
    PubMed     Abstract available


  255. DEMAREZ C, Gerard C, Cordi S, Poncy A, et al
    MiR-337-3p controls hepatobiliary gene expression and transcriptional dynamics during hepatic cell differentiation.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29475.
    PubMed     Abstract available


  256. MONCSEK A, Al-Suraih MS, Trussoni CE, O'Hara SP, et al
    Targeting senescent cholangiocytes and activated fibroblasts with Bcl-xL inhibitors ameliorates fibrosis in Mdr2-/- mice.
    Hepatology. 2017 Aug 12. doi: 10.1002/hep.29464.
    PubMed     Abstract available


    July 2017
  257. GU J, Jeong S, Xia Q
    Intrahepatic cholangiocarcinoma arising from HBV Infection may be a highly selected population for liver transplantation.
    Hepatology. 2017 Jul 31. doi: 10.1002/hep.29413.
    PubMed    


  258. FIOROTTO R, Amenduni M, Mariotti V, Fabris L, et al
    Src kinase inhibition reduces inflammatory and cytoskeletal changes in DeltaF508 human cholangiocytes and improves CFTR correctors efficacy.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29400.
    PubMed     Abstract available


  259. THOMPSON MD, Moghe A, Cornuet P, Marino R, et al
    beta-catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29371.
    PubMed     Abstract available


  260. PURI P, Daita K, Joyce A, Mirshahi F, et al
    The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Hepatology. 2017 Jul 11. doi: 10.1002/hep.29359.
    PubMed     Abstract available


  261. PELLAT A, Vaquero J, Fouassier L
    Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29350.
    PubMed     Abstract available


    June 2017
  262. WANG DQ, Portincasa P, Tso P
    Transintestinal cholesterol excretion (TICE): A secondary, non-biliary pathway contributing to reverse cholesterol transport.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29341.
    PubMed    


  263. DAWSON PA
    Hepatic bile acid uptake in humans and mice: Multiple pathways and expanding potential role for gut-liver signaling.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29325.
    PubMed    


  264. ALVARO D
    The challenge of cholangiocarcinoma diagnosis: the turning point is in extracellular vesicles?
    Hepatology. 2017 Jun 12. doi: 10.1002/hep.29314.
    PubMed    


  265. CHOI TY, Khaliq M, Tsurusaki S, Ninov N, et al
    Bmp Signaling Governs Biliary-Driven Liver Regeneration in Zebrafish via Tbx2b and Id2a.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29309.
    PubMed     Abstract available


  266. LIBERAL R, Grant CR, Yuksel M, Graham J, et al
    Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis/Autoimmune Sclerosing Cholangitis.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29307.
    PubMed     Abstract available


  267. QIAN Y, Yao W, Yang T, Yang Y, et al
    aPKC-iota/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma.
    Hepatology. 2017 Jun 2. doi: 10.1002/hep.29296.
    PubMed     Abstract available


    May 2017
  268. ARBELAIZ A, Azkargorta M, Krawczyk M, Santos-Laso A, et al
    Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
    Hepatology. 2017 May 26. doi: 10.1002/hep.29291.
    PubMed     Abstract available


  269. CHIANG JYL
    Linking long non-coding RNA to control bile acid signaling and cholestatic liver fibrosis.
    Hepatology. 2017 May 24. doi: 10.1002/hep.29289.
    PubMed    


  270. TOMINAGA K, Kamimura K, Sakamaki A, Terai S, et al
    Intraductal Papillary Neoplasm of the Bile Duct: A Rare Liver Tumor Complicated by Malignancy.
    Hepatology. 2017 May 18. doi: 10.1002/hep.29266.
    PubMed    


  271. GUO GL
    Why are females more susceptible to cholestasis-induced liver injury - Could it be LncRNA H19?
    Hepatology. 2017 May 15. doi: 10.1002/hep.29255.
    PubMed    


  272. SLIJEPCEVIC D, Roscam Abbing RLP, Katafuchi T, Blank A, et al
    Hepatic uptake of conjugated bile acids is mediated by both NTCP and OATPs and modulated by intestinal sensing of plasma bile acid levels in mice.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29251.
    PubMed     Abstract available


  273. TANAKA T, Zhang W, Sun Y, Shuai Z, et al
    Autoreactive Monoclonal Antibodies from Patients with Primary Biliary Cholangitis Recognize Environmental Xenobiotics.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29245.
    PubMed     Abstract available


    April 2017
  274. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Abstract available


  275. MIELI-VERGANI G, Vergani D
    The riddle of juvenile sclerosing cholangitis.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29208.
    PubMed    


  276. DENEAU MR, El-Matary W, Valentino PL, Abdou R, et al
    The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29204.
    PubMed     Abstract available


  277. LEVY C
    Primary biliary cholangitis: Treatment options finally expand.
    Hepatology. 2017;65:1405-1407.
    PubMed    


    March 2017
  278. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Abstract available


  279. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Abstract available


    February 2017
  280. LI H, Zhou ZQ, Yang ZR, Tong DN, et al
    MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
    Hepatology. 2017 Feb 14. doi: 10.1002/hep.29116.
    PubMed     Abstract available


  281. KRAWCZYK M, Rau M, Grunhage F, Schattenberg JM, et al
    The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29100.
    PubMed    


    January 2017
  282. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Abstract available


  283. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Abstract available


  284. SHUAI Z, Wang J, Badamagunta M, Choi J, et al
    The Fingerprint of Antimitochondrial Antibodies and the Etiology of Primary Biliary Cholangitis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29059.
    PubMed     Abstract available


  285. BJORNSSON ES, Jonasson JG
    Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome: Rare but has severe consequences.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29040.
    PubMed    


  286. VIVEIROS A, Reiterer M, Schaefer B, Finkenstedt A, et al
    CCBE1 Mutation causing Sclerosing Cholangitis - Expanding the Spectrum of Lymphedema-Cholestasis Syndrome.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29037.
    PubMed    


  287. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Abstract available


    December 2016
  288. WANG KS, Tiao G, Bass LM, Hertel PM, et al
    Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29019.
    PubMed     Abstract available


  289. HAUSSINGER D, Keitel V
    Dual role of the bile acid receptor TGR5 for hepatic lipid metabolism in feast and famine.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29017.
    PubMed    


  290. QIU YL, Gong JY, Feng JY, Wang RX, et al
    Defects in MYO5B are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29020.
    PubMed     Abstract available


  291. BRANDI G, De Lorenzo S, Palloni A, Biasco G, et al
    Aspirin for cholangiocarcinoma prevention: new targets to shift the dogma from ascertained risk to possible prevention (Reply to: Risk Factors for Cholangiocarcinoma: Aspirin-use and the Risk of Cholangiocarcinoma).
    Hepatology. 2016 Dec 23. doi: 10.1002/hep.28999.
    PubMed    


  292. TRAUNER M, Fuchs CD, Halilbasic E, Paumgartner G, et al
    New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28991.
    PubMed     Abstract available


  293. GUPTA R, Gupta J
    Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28994.
    PubMed    


  294. SAPISOCHIN G, Bruix J
    In response to: Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28993.
    PubMed    


  295. FAN W, Yang H, Liu T, Wang J, et al
    Prohibitin 1 Suppresses Liver Cancers Tumorigenesis in Mice and Human Hepatocellular and Cholangiocarcinoma cells.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28964.
    PubMed     Abstract available


  296. BONKOVSKY HL, Kleiner DE, Gu J, Odin JA, et al
    Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28967.
    PubMed     Abstract available


  297. JANSEN PL, Ghallab A, Vartak N, Reif R, et al
    The ascending pathophysiology of cholestatic liver disease.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28965.
    PubMed     Abstract available


    November 2016
  298. DE VRIES EM, de Krijger M, Farkkila M, Arola J, et al
    Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; An International Cohort Study.
    Hepatology. 2016 Nov 23. doi: 10.1002/hep.28963.
    PubMed     Abstract available


  299. MOHANTY SK, Donnelly B, Lobeck I, Walther A, et al
    The SRL peptide of Rhesus Rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia.
    Hepatology. 2016 Nov 17. doi: 10.1002/hep.28947.
    PubMed     Abstract available


  300. SAMUR S, Klebanoff M, Banken R, Pratt DS, et al
    Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28932.
    PubMed     Abstract available


  301. GRADILONE SA
    Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28925.
    PubMed    


  302. ALTAII H, Al-Kindi SG, Oliveira GH, Yaqoob Z, et al
    Aspirin use and risk of cholangiocarcinoma: External validation with big data.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28920.
    PubMed    


  303. YAN S, Tang J, Zhang Y, Wang Y, et al
    Prostaglandin E2 promotes hepatic bile acid synthesis by an E prostanoid receptor 3-mediated hepatocyte nuclear receptor 4alpha/cholesterol 7alpha-hydroxylase pathway in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28928.
    PubMed     Abstract available


    October 2016
  304. DESAI M, Mathur B, Eblimit Z, Vasquez H, et al
    Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28890.
    PubMed     Abstract available


  305. ZHANG L, Yang Z, Trottier J, Barbier O, et al
    LncRNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate Shp mRNA decay.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28882.
    PubMed     Abstract available


    September 2016
  306. DAHLQVIST G, Gaouar F, Carrat F, Meurisse S, et al
    Large-scale characterization study of patients with antimitochondrial antibodies but non-established primary biliary cholangitis.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28859.
    PubMed     Abstract available


  307. LAGES CS, Simmons J, Maddox A, Jones K, et al
    The dendritic cell-Th17-macrophage axis controls cholangiocyte injury and disease progression in murine and human biliary atresia.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28851.
    PubMed     Abstract available


  308. KULKARNI SR, Soroka CJ, Hagey LR, Boyer JL, et al
    Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid fed mouse model of cholestasis.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28826.
    PubMed     Abstract available


  309. MCDANIEL K, Meng F, Wu N, Sato K, et al
    Forkhead box A2 regulated biliary heterogeneity and senescence during cholestatic liver injury.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28831.
    PubMed     Abstract available


  310. KAMINSKY P, Preiss J, Sasatomi E, Gerber DA, et al
    Biliary Adenofibroma: A Rare Hepatic Lesion with Malignant Features.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28818.
    PubMed    


  311. FIOROTTO R, Villani A, Kourtidis A, Scirpo R, et al
    CFTR controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28817.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: